**

How charmingly naive they were in 2024, those earnest researchers who thought they'd cracked the code of cardiovascular mortality in dialysis patients. Armed with their primitive statistical models and quaint faith in single-nutrient solutions, they proclaimed victory over death itself. Fast-forward to 2091, and BioNex Corporation is peddling the exact same snake oil—except now it's "quantum-optimized" and comes with a complimentary consciousness backup.

The parallels are almost insulting in their banality. Back then, Futura Sciences breathlessly reported on "unexpected results rarely observed" in dialysis populations. Today, our own Council-sanctioned media outlets parrot identical phrases about BioNex's latest cardio-protective compound, now conveniently synthesized by their Martian bio-farms and delivered through nanoscale precision targeting.

But here's the inconvenient truth nobody wants to discuss at those insufferable Trans-Planetary Health Summits: we're still losing dialysis patients at roughly the same rates our ancestors did seven decades ago. Sure, we can now back up their memories before the inevitable cardiac event, and yes, their synthetic replacement bodies perform admirably. But death? Death remains stubbornly unimpressed by our technological theater.

Dr. Kenji Nakamura-7, lead researcher at the Institute for Metabolic Archaeology, offered this deliciously honest assessment: "We've essentially weaponized hope. Every generation discovers the same fundamental nutritional interactions, wraps them in the latest technological buzzwords, and sells them as revolutionary. The only thing that's truly evolved is our marketing sophistication."

The 2024 study—lost now in the data purges following the Great Connectivity Crisis of 2067—supposedly identified a dietary compound that dramatically reduced cardiovascular events. Sound familiar? It should. We've had seventeen "breakthrough" nutrients since then, each heralded as the definitive solution. Omega-7 fatty acids. Quantum-stabilized polyphenols. Biomimetic peptide complexes. The list reads like a graveyard of abandoned pharmaceutical patents.

What's particularly galling is how little our fundamental understanding has actually progressed. We can teleport quantum information across star systems, engineer consciousness into crystalline matrices, and terraform atmospheric compositions, yet we remain mystified by the basic mechanics of keeping a failing kidney from killing its host.

Perhaps the real scandal isn't our technological limitations—it's our pathological inability to admit them. The Council of Species loves to trumpet humanity's post-scarcity achievements, but scarcity of honesty appears to be our most persistent shortage. We've created a culture where admitting ignorance is career suicide, where every research grant must promise revolutionary breakthroughs, where incremental progress is dismissed as insufficient.

The dialysis patients of 2091 deserve better than recycled optimism dressed up in quantum terminology. They deserve researchers brave enough to say: "We don't know, but we're genuinely trying to find out." Instead, they get press releases that could have been written in 2024, 2050, or any year in between.

Maybe the real breakthrough will come when we finally learn to value uncomfortable questions over comfortable answers.

**MOTS_CLES:** dialysis, cardiovascular mortality, nutrient therapy, medical delusion, technological stagnation